EPIDUO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EPIDUO (EPIDUO).
Epiduo is a fixed-dose combination of adapalene, a retinoid that binds to retinoic acid receptors (RAR-β, RAR-γ) and normalizes follicular cell differentiation, and benzoyl peroxide, an oxidizing agent with bactericidal activity against Propionibacterium acnes and mild keratolytic effect.
| Metabolism | Adapalene is metabolized primarily by CYP2C9 and to a lesser extent by CYP3A4, undergoing O-demethylation and hydroxylation. Benzoyl peroxide degrades rapidly to benzoic acid, which is conjugated with glycine and excreted in urine. |
| Excretion | Renal: negligible; fecal: not applicable; biliary: not applicable. Adapalene and benzoyl peroxide are not absorbed significantly; absorbed adapalene is excreted primarily via bile (fecal) as metabolites. |
| Half-life | Adapalene: terminal elimination half-life 7-12 hours (mean 9 hours) after topical application; no systemic accumulation with once-daily dosing. |
| Protein binding | Adapalene: >95% bound to plasma proteins (mainly albumin); benzoyl peroxide not absorbed. |
| Volume of Distribution | Adapalene: 0.5-1.0 L/kg (systemically absorbed fraction); clinically indicates minimal systemic distribution due to low absorption. |
| Bioavailability | Topical: negligible systemic bioavailability (<1%) for adapalene; benzoyl peroxide is metabolized to benzoic acid and excreted renally. |
| Onset of Action | Topical: reduction in inflammatory lesions (comedones, papules, pustules) begins after 4-8 weeks of daily application; peak effect at 12 weeks. |
| Duration of Action | Topical: 24 hours with once-daily application; sustained improvement with continued use; lesions may recur 2-4 weeks after discontinuation. |
Apply a thin layer to affected areas of the face and/or trunk once daily in the evening.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | Approved for use in patients aged 9 years and older; apply a thin layer to affected areas once daily in the evening. |
| Geriatric use | No specific dosage adjustments; use with caution due to potential for increased skin sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EPIDUO (EPIDUO).
| Breastfeeding | Both adapalene and benzoyl peroxide have negligible systemic absorption after topical application. M/P ratio: Not determined due to undetectable levels. Excretion into breast milk is unlikely. However, caution is advised; apply to smallest area possible and avoid application to the breast area to prevent infant exposure. |
| Teratogenic Risk | Adapalene: Oral retinoids are teratogenic; however, topical adapalene has minimal systemic absorption (approximately 0.07% of applied dose). No increased risk of fetal malformations has been observed in human case series or animal studies with topical use. Benzoyl peroxide: No teratogenic effects reported; minimal percutaneous absorption. Overall, the combination is considered low risk during pregnancy, but use should be limited to small areas and shortest duration necessary, especially in the first trimester. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to adapalene, benzoyl peroxide, or any component of the formulation"]
| Precautions | ["Avoid excessive sun exposure and use of sunlamps; use sunscreen daily","May cause local skin reactions (erythema, scaling, dryness, stinging/burning) initially; reduce frequency or discontinue if severe","Avoid contact with eyes, lips, mouth, and mucous membranes","Do not use on broken, eczematous, or sunburned skin","Potential for photosensitization; avoid concurrent use with other photosensitizing agents"] |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required. Routine prenatal care is sufficient. Monitor maternal skin for adverse reactions such as irritation, peeling, or photosensitivity. |
| Fertility Effects | No known effects on fertility. Animal studies with oral adapalene show no impairment of fertility; no human data suggest an impact from topical use. |